With Relapsing-remitting Multiple Sclerosis Regulation of Th17 Responses in Patients in the Β the Role of Endogenous Ifn

[1]  Hongtu Zhu,et al.  Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing–Remitting Multiple Sclerosis , 2013, The Journal of Immunology.

[2]  A. Reder,et al.  Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis , 2012, Journal of the Neurological Sciences.

[3]  M. David,et al.  Immunomodulatory functions of type I interferons , 2012, Nature Reviews Immunology.

[4]  T. Owens,et al.  Interferon regulatory factor-7 modulates experimental autoimmune encephalomyelitis in mice , 2011, Journal of Neuroinflammation.

[5]  Guangjie Chen,et al.  Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. , 2011, Immunity.

[6]  N. Tubridy,et al.  IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells , 2011, Brain, Behavior, and Immunity.

[7]  Yonggang Sha,et al.  B Cells as a Therapeutic Target for IFN-β in Relapsing–Remitting Multiple Sclerosis , 2011, The Journal of Immunology.

[8]  F. Barkhof,et al.  Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS , 2010, Neurology.

[9]  R. Flavell,et al.  Regulating human Th17 cells via differential expression of IL-1 receptor. , 2010, Blood.

[10]  J. Río,et al.  A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. , 2009, Brain : a journal of neurology.

[11]  H. Nie,et al.  Regulatory effects of IFN‐β on production of osteopontin and IL‐17 by CD4+ T Cells in MS , 2009, European journal of immunology.

[12]  R. Gold,et al.  Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis , 2009, Clinical and experimental immunology.

[13]  P. Hertzog,et al.  Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus , 2009, Arthritis research & therapy.

[14]  Laura Conti,et al.  T‐helper 17 cells expand in multiple sclerosis and are inhibited by interferon‐β , 2009, Annals of neurology.

[15]  G. Rosati,et al.  Multiple sclerosis: reduced proportion of circulating plasmacytoid dendritic cells expressing BDCA-2 and BDCA-4 and reduced production of IL-6 and IL-10 in response to herpes simplex virus type 1 , 2008, Multiple sclerosis.

[16]  M. Shinohara,et al.  Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. , 2008, Immunity.

[17]  B. Becher,et al.  Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. , 2008, Immunity.

[18]  S. Miller,et al.  Cutting Edge: Central Nervous System Plasmacytoid Dendritic Cells Regulate the Severity of Relapsing Experimental Autoimmune Encephalomyelitis1 , 2008, The Journal of Immunology.

[19]  G. Cheng,et al.  The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. , 2008, The Journal of clinical investigation.

[20]  Roland Martin,et al.  Genomics in multiple sclerosis—Current state and future directions , 2007, Journal of Neuroimmunology.

[21]  M. Crow,et al.  Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. , 2006, Arthritis and rheumatism.

[22]  R. Gold,et al.  Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. , 2006, Brain : a journal of neurology.

[23]  F. Mihara,et al.  Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. , 2005, Brain : a journal of neurology.

[24]  L. Staudt,et al.  Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. , 2003, Brain : a journal of neurology.

[25]  D. Tough,et al.  Links between innate and adaptive immunity via type I interferon. , 2002, Current opinion in immunology.

[26]  Jorge R. Oksenberg,et al.  Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.

[27]  L. Staudt,et al.  Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genes , 2001, Annals of neurology.

[28]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[29]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[30]  F. Barkhof,et al.  Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.

[31]  M. Rewers,et al.  Heterophile anti-mouse immunoglobulin antibodies may interfere with cytokine measurements in patients with HLA alleles protective for type 1A diabetes. , 1999, Diabetes.

[32]  K. Wessel,et al.  Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis , 1997, Journal of the Neurological Sciences.

[33]  H. Wiendl,et al.  Multiple Sclerosis the Dysfunctional Immune Regulation in Plasmacytoid Dendritic Cells Characterizes Phenotypically Different Subsets of An Imbalance of Two Functionally and , 2010 .

[34]  Jia Newcombe,et al.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. , 2008, The American journal of pathology.

[35]  T. Taniguchi,et al.  IRF family of transcription factors as regulators of host defense. , 2001, Annual review of immunology.

[36]  R. Zawatzky,et al.  Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-alpha and IFN-beta. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[37]  D. Hafler,et al.  Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. , 1998, Nature.

[38]  G. Trinchieri,et al.  Interferon (cid:2) / (cid:3) and Interleukin 12 Responses to Viral Infections: Pathways Regulating Dendritic Cell Cytokine Expression In Vivo , 2022 .